Patients underwent tumor molecular profiling at screening and were assigned to either a biomarker-matched cohort (durvalumab–ceralasertib: ATM altered; durvalumab–olaparib: homologous recombination repair (HRR) altered, STK11/LKB1 altered; durvalumab–oleclumab: high CD73 expression) or a biomarker-nonmatched group. This evidence concerns the gene STK11 and neoplasm.